[Thrombosis and lung cancer].
Venous thromboembolism (TE) is a frequent occurrence in lung cancer patients and can be precipitated by venous stasis, the activation of clotting cascades by pro-coagulant tumour factors and by vascular injury due to chemotherapy and central venous catheters. Subcutaneous low molecular weight heparin (LMWH) has replaced intravenous unfractionated heparin in the treatment of acute TE. The use of long-term LMWH is recommended to prevent the recurrence of TE. Prophylactic treatment is indicated in patients undergoing surgery or hospitalised. Heparin appears to have distinct anti-neoplastic as well as anticoagulant effects, which benefit overall survival.
Bréchot
J-M
JM
Service d'Oncologie Médicale, Hôpital Avicenne, Bobigny, France. anne-marie.brechot@avc.ap-hop-paris.fr
D000925:Anticoagulants / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications*; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control
D000925:Anticoagulants; D006493:Heparin